嘉应制药：因关联交易未按规定履行相关决策程序和信息披露义务，收广东证监局警示函

Core Viewpoint - Recently, Jiaying Pharmaceutical (002198) received a warning letter from the Guangdong Supervision Bureau of the China Securities Regulatory Commission regarding violations related to related party transactions and disclosure obligations [1] Group 1: Company Violations - From September 2024 to December 2024, the company engaged in traditional Chinese medicine transactions with Guangdong Gonghe Pharmaceutical Co., Ltd., involving an amount of approximately 8.7558 million yuan, which accounts for 1.15% of the company's most recent audited net assets [1] - The related party transaction was not conducted in accordance with the required decision-making procedures and information disclosure obligations [1] Group 2: Responsible Individuals - The company's chairman, Li Neng, general manager, You Yongping, and former board secretary, Xiao Qiaoxia, failed to fulfill their duties and obligations, violating multiple provisions of the Stock Listing Rules (2024 Revision) [1] - The general manager's close family member, Liu Limin, was the controlling shareholder of Gonghe Pharmaceutical, which is a related legal entity of the company [1]